These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37649096)
21. Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability. Tang J; Sheng J; Zhang Q; Ji Y; Wang X; Zhang J; Wu J; Song J; Bai X; Liang T J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849200 [TBL] [Abstract][Full Text] [Related]
22. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208 [TBL] [Abstract][Full Text] [Related]
23. Coexpression of Xu T; Wang C; Chen X; Bai J; Wang E; Sun M Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720 [TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794 [TBL] [Abstract][Full Text] [Related]
28. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368 [TBL] [Abstract][Full Text] [Related]
29. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306 [TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
31. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594 [TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916 [TBL] [Abstract][Full Text] [Related]
33. Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death. Wang Y; Zhang H; Du G; Luo H; Su J; Sun Y; Zhou M; Shi B; Li HQX; Jiang H; Li Z Mol Ther; 2023 Mar; 31(3):701-714. PubMed ID: 36523165 [TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy. Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263 [TBL] [Abstract][Full Text] [Related]
36. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. Lin YJ; Mashouf LA; Lim M Front Immunol; 2022; 13():817296. PubMed ID: 35265074 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. Li T; Wang J BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954 [TBL] [Abstract][Full Text] [Related]
38. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related]
39. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643 [TBL] [Abstract][Full Text] [Related]
40. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Du X; Darcy PK; Wiede F; Tiganis T Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]